industry with the pharmaceuticals industry leading the healthcare sector. The rising incidence of various diseases in the areas of Cardiovascular devices (CVD), respiratory, oncology, neurology, and many others have necessitated the need for faster and better medical devices for treatment and diagnosis...
BEIJING, March 17 (Xinhua) -- A list of China's top 10 medical science and technology news events of 2019 was released by a national health newspaper on Tuesday. Clinical trials of an innovative drug, an artificial intelligence (AI)-assisted diagnosis platform and gene-edited diseased monkeys ...
Additionally, BD acquired Cytognos, a privately held company specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases. This acquisition granted BD access to advanced assays licensed from the EuroFlow ...
The IVD Market segment is expected to account for the largest share of the Top 10 Medical device technologies market in 2021 The gradual transition from centralised testing to point-of-care testing, rising concern over early disease diagnosis in developing nations, the emergence of rapid PoC techno...
Insuring more Texans and building fewer hospitals will help, says Ken Shine, who oversees UT Southwestern and other facilities.Dallas News
” Klein said he feels the medical community is on the verge of a cure, but still faces challenges with diagnosis. “The biggest problem we face in prostate cancer is the over-detection of nonlethal cancers,” he said. “Currently, we don’t have the tools to tell someone ...
收拾心情,一起来看全球医疗器械TOP 10企业2022年最新表现。 *按实时汇率换算:1瑞士法郎=1.102美元;1欧元=1.0833美元。以财报发布为基准。 *美敦力2022财年区间为2021年4月25日到2022年4月29日。 *碧迪医疗、西门子医疗2022财年区间为2021年10月1日到2022年9月30日。 *飞利浦的医疗营收仅考虑Diagnosis&Treatment和...
*碧迪医疗、西门子医疗2022财年区间为2021年10月1日到2022年9月30日。 *飞利浦的医疗营收仅考虑Diagnosis&Treatment和Connected Care两个部分数据。 *研发费用均指公司/集团总研发费用支出。各企业统计口径不一,数据仅供参考。 2022年,大健康行业基本回归常态化,各企业新冠相关营收占比大幅下降。
*碧迪医疗、西门子医疗2022财年区间为2021年10月1日到2022年9月30日。 *飞利浦的医疗营收仅考虑Diagnosis&Treatment和Connected Care两个部分数据。 *研发费用均指公司/集团总研发费用支出。各企业统计口径不一,数据仅供参考。 2022年,大健康行业基本回归常态化,各企业新冠相关营收占比大幅下降。
Final selection of an antibiotic treatment regimen for drug-resistant bacteria should always be tailored for a patient according to the antimicrobial susceptibility test result and the expertise of a medical professional. Treatment selection depends upon:...